Table 2. Patient characteristics of the eligible studies.
| Study | No. of patients | Median age, range (years) | Gender (male/female) |
Intravesical therapy (no.) | Median follow-up, range (months) |
|---|---|---|---|---|---|
| Asakura [20] | 104 | 63 (mean), 28–90 | 78/26 | Chemotherapy (6) | 42 (mean), 3–134 |
| Lee [21] | 32 | NA, 30–81 | 28/4 | BCG (32) | NA |
| Pfister [22] | 244 | 65.1 (mean), NA | NA | No | 47 (mean), NA |
| Tomobe [23] | 50 | 63.9 (mean), 22–88 | 43/7 | Chemotherapy or BCG (32) | 44 (mean), 5–80 |
| Wu [24] | 86 | NA | NA | NA | NA |
| Blanchet [25] | 70 | 62.6 (mean), 21–84 | 66/4 | BCG (57) | 64, 12–111 |
| Kamai [26] | 86 | NA | NA | MMC, doxorubicin or BCG (NA) | 50, 3–124 |
| Kilicli-Camur [27] | 118 | 60.2 (mean), 29–86 | NA | NA | 31.4 (mean), 24–60 |
| Sgambato [28] | 96 | 68 (mean), 29–92 | 83/13 | BCG (NA) | 50 (mean), 24–102 |
| Yan [29] | 270 | 71 (mean), NA | 196/71, unknown (3) | BCG (66) | 19, (1–54) |
| Dybowski [30] | 45 | NA | NA | NA | 64, 1–82 |
| Santos [31] | 159 | 66, 21–88 | 115/44 | Chemotherapy (65), BCG (17) | 46.5, 4–123 |
| Su [32] | 79 | 64, 34–91 | 66/13 | MMC or Adriamycin (74) | 48.7 (mean), 4–78 |
| Mhawech [33] | 49 | 70.3 (mean), 52–90 | 44/5 | BCG (7) | 12, 3–77 |
| Krüger [34] | 73 | 68, NA | 60/13 | BCG (73) | NA |
| Theodoropoulos [35] | 140 | 69, 23–89 | 107/33 | Epirubicin or BCG (114) | 41, 8–131 |
| Gonzalez-Campora [36] | 147 | 66 (mean), 30–95 | 127/20 | BCG (NA) | 75 (mean), 5–12 yr |
| Quintero [37] | 164 | 61 (mean), 29–93 | 143/21 | BCG (NA) | 75, 60–144 |
| Yin [38] | 101 | NA | 81/20 | BCG (101) | 54, 20–68.6 (10–90% percentiles) |
| Maeng [39] | 55 | 67 (mean), 33–84 | 40/15 | NA | 26.2 (mean), 3–70 |
| Miyake [40] | 109 | 68.5 (mea), 36–94 | 19/14 | Anthracycline (16), doxorubicin (1), epirubicin (13), pirarubicin (2), BCG (19) | 48, 1–99 |
| Seo [41] | 129 | 64.2 (38–88) | 104/25 | MMC (129) | 48.6 (mean), 6.1–96 |
| van Rhijn [10] | 230 | 65.1 (mean), NA | 175/55 | NA | 8.6 yr, 6.6–11.3 yr (IQR) |
| Behnsawy [42] | 161 | NA | 137/24 | Unknown regimen (49) | 47, 13–93 |
| Wosnitzer [43] | 32 | 70.3, 44–89 | 25/7 | Docetaxel (17), nanoparticle albumin-bound docetaxel (15) | 22, 11–75 |
| Acikalin [6] | 68 | 63, 35–85 | 66/2 | NA | 51, 12–132 |
| Chen [11] | 72 | 61.3 (mean), 27–87 | 58/14 | MMC, epirubicin, pirarubicin (NA) | 63.4 (mean), 16–93 |
| Ogata [44] | 43 | 70, 39–85 | 35/8 | NA | NA, 12–71 |
| Oderda [45] | 192 | 73.2 (mean), NA | 166/26 | BCG (192) | 100, 2–229 |
| Okazoe [46] | 71 | 72, 41–95 | 59/12 | Unknown regimen (31) | 9.8, 1.0–51.8 |
| Park [47] | 70 | 66, 31–85 | 53/8 | BCG (70) | 60, 6–217 |
| Ruan [48] | 126 | 64.5 (mean), 29–90 | 103/23 | NA | NA |
| Ben Abdelkrim [14] | 71 | 63.1 (mean), 39–88 | 67/4 | NA | 28, 3–77 |
| Bertz [18] | 309 | 71.7, 38–87 | 237/72 | BCG (309) | 49, 5–172 |
| Ding [15] | 332 | 67, 21–92 | 273/59 | NA | 47, 2–124 |
| Mangrud [49] | 193 | 74, 39–95 | 148/45 | BCG (NA) | 75, 1–127 |
| Pan [50] | 605 | 71 (mean), 23–92 | 511/94 | MMC (272), doxorubicin (67), epirubicin (130), BCG (132) | NA |
| Özyalvaçli [16] | 90 | NA | 83/7 | NA | 32.8, 36.2–103.6 (IQR) |
| Poyet [17] | 158 | 69.5, 32–92 | 131/43 | NA | 110.6, 32.4–266.8 |
NA: not available, BCG: bacille Calmette-Guérin, MMC: mitomycin C, IQR: interquartile range.